Pacific Biosciences of California
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Pacific Biosciences of California generated cash of -$259,173,000, which is more than the previous year. Cash used in financing activities reached the amount of $108,891,000 last year. Net change in cash is therefore -$148,400,000.
Cash Flow
| 2014 | -51.46M | 19.56M | 41.99M |
|---|---|---|---|
| 2015 | -47.88M | 8.60M | 36.46M |
| 2016 | -67.92M | -14.86M | 65.92M |
| 2017 | -67.51M | -1.54M | 68.80M |
| 2018 | -66.43M | -38.41M | 107.18M |
| 2019 | -78.31M | 62.04M | 26.54M |
| 2020 | 19.50M | -219.32M | 251.83M |
| 2021 | -111.18M | -678.53M | 1.16B |
| 2022 | -263.21M | 116.08M | 9.62M |
| 2023 | -259.17M | 4.60M | 108.89M |
PACB Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 328.31M | 465.81M | 85.94M | 33.92M | 23.34M | 21.00M | 16.76M | 33.62M | 36.44M | 26.36M |
Operating activities | ||||||||||
Net income | -306.73M | -314.24M | -181.22M | 29.40M | -84.13M | -102.56M | -92.18M | -74.37M | -31.69M | -66.16M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 26.53M | 17.31M | 11.58M | 9.30M | 9.94M | 7.21M | 8.44M | 3.87M | 3.67M | 4.22M |
Stock-based compensation expense | 72.11M | 78.61M | 73.35M | 17.53M | 16.40M | 23.15M | 20.35M | 19.56M | 13.84M | 9.94M |
| Deferred income tax benefit | 72.11M | 78.61M | 73.35M | 17.53M | 16.40M | 23.15M | 20.35M | 19.56M | 13.84M | 9.94M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -17.82M | 5.45M | -7.16M | -1.60M | -6.67M | 4.83M | -2.01M | -6.17M | -1.73M | -660K |
Inventories | -13.84M | -33.90M | -12.43M | -1.09M | 3.91M | 3.62M | -8.44M | -6.15M | -2.46M | -1.28M |
Accounts payable | 206K | 1.02M | 14.86M | -789K | 1.71M | -2.23M | 764K | 3.40M | -716K | 3.89M |
Cash generated by operating activities | -259.17M | -263.21M | -111.18M | 19.50M | -78.31M | -66.43M | -67.51M | -67.92M | -47.88M | -51.46M |
Investing activities | ||||||||||
Purchases Of Investments | -756.56M | -442.78M | -988.04M | -373.28M | -57.72M | -122.18M | -86.33M | -95.84M | -84.57M | -126.41M |
Investments In Property Plant And Equipment | -8.84M | -16.92M | -5.93M | -1.03M | -2.83M | -1.85M | -10.43M | -8.20M | -3.00M | -1.60M |
Acquisitions Net | -102K | 179K | -319.79M | 218.28M | -64.88M | 0 | 41K | 0 | 36K | 0 |
Cash generated by investing activities | 4.60M | 116.08M | -678.53M | -219.32M | 62.04M | -38.41M | -1.54M | -14.86M | 8.60M | 19.56M |
Financing activities | ||||||||||
Common Stock Issued | 189.2M | 11.23M | 326.65M | 187.47M | 8.54M | 97.53M | 64.39M | 0 | 29.1M | 38.02M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -1.84M | -1.60M | -895.17M | -16M | 0 | 0 | -4.5M | 0 | 0 | 0 |
Cash used in financing activities | 108.89M | 9.62M | 1.16B | 251.83M | 26.54M | 107.18M | 68.80M | 65.92M | 36.46M | 41.99M |
Net Change In Cash | -148.4M | -137.50M | 379.87M | 52.02M | 10.28M | 2.33M | -258K | -16.86M | -2.82M | 10.08M |
Cash at end of period | 179.91M | 328.31M | 465.81M | 85.94M | 33.62M | 23.34M | 16.50M | 16.76M | 33.62M | 36.44M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |